David A Verbel
Overview
Explore the profile of David A Verbel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tibes R, Borad M, Dutcus C, Reyderman L, Feit K, Eisen A, et al.
Br J Cancer
. 2018 Jun;
118(12):1580-1585.
PMID: 29867224
Background: This phase 1 first-in-human study aimed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and safety of E6201, and to establish recommended dosing in patients with advanced solid tumours,...
2.
Gidal B, Maganti R, Laurenza A, Yang H, Verbel D, Schuck E, et al.
Epilepsy Res
. 2017 May;
134:41-48.
PMID: 28535410
Objectives: Perampanel, a selective, noncompetitive AMPA receptor antagonist, is indicated as adjunctive therapy for the treatment of partial seizures with or without secondarily generalized seizures and primary generalized tonic-clonic seizures...
3.
Cordon-Cardo C, Kotsianti A, Verbel D, Teverovskiy M, Capodieci P, Hamann S, et al.
J Clin Invest
. 2007 Jun;
117(7):1876-83.
PMID: 17557117
We have developed an integrated, multidisciplinary methodology, termed systems pathology, to generate highly accurate predictive tools for complex diseases, using prostate cancer for the prototype. To predict the recurrence of...
4.
Gurrieri C, Capodieci P, Bernardi R, Scaglioni P, Nafa K, Rush L, et al.
J Natl Cancer Inst
. 2004 Feb;
96(4):269-79.
PMID: 14970276
Background: The PML gene is fused to the RARalpha gene in the vast majority of acute promyelocytic leukemias (APL) and has been implicated in the control of key tumor-suppressive pathways....
5.
Smaletz O, Scher H, Small E, Verbel D, McMillan A, Regan K, et al.
J Clin Oncol
. 2002 Sep;
20(19):3972-82.
PMID: 12351594
Purpose: To develop a pretreatment prognostic model for survival of patients with progressive metastatic prostate cancer after castration using parameters that are measured during routine clinical management. Patients And Methods:...
6.
Verbel D, Heller G, Kelly W, Scher H
Clin Cancer Res
. 2002 Aug;
8(8):2576-9.
PMID: 12171886
Purpose: Post-therapy changes in prostate-specific antigen(PSA) have been proposed as surrogates for survival in clinical trials due to observed statistical associations. However, association alone does not satisfy the conditions of...
7.
Satagopan J, Verbel D, Venkatraman E, Offit K, Begg C
Biometrics
. 2002 Mar;
58(1):163-70.
PMID: 11890312
The goal of this article is to describe a two-stage design that maximizes the power to detect gene-disease associations when the principal design constraint is the total cost, represented by...